Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Acute Myocardial Infarction
NCT02938949Phase 4Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypercholesterolemia comparing Alirocumab + Atorvastatin with Placebo + Atorvastatin (2 arms). Primary endpoint: Changes in Low-density Lipoprotein Cholesterol at 14 days. Started Jan 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02938949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938949.